Latest News about SNY
Recent news which mentions SNY
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
October 18, 2022
From Benzinga
From Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
October 13, 2022
From Motley Fool
From Benzinga
2 Top Healthcare Stocks to Buy Right Now
October 08, 2022
From Motley Fool
7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market
October 07, 2022
From InvestorPlace
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
October 06, 2022
From Benzinga
From Motley Fool
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
September 29, 2022
From Benzinga
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
September 20, 2022
From Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
September 19, 2022
From Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
September 19, 2022
From Motley Fool
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
From Benzinga
From Benzinga
What's Moderna's Next Billion-Dollar Market? The Answer May Surprise You.
September 14, 2022
From Motley Fool
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
September 08, 2022
From Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
September 06, 2022
From Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
September 06, 2022
From Benzinga
From Benzinga
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval
September 01, 2022
Tickers
SNY
From Benzinga
From Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
From Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
August 30, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
August 25, 2022
From Benzinga
From Benzinga
From Benzinga
The Rise and Fall of Novavax
August 21, 2022
From Motley Fool
Stocks That Hit 52-Week Lows On Thursday
August 18, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.